Hepatic Angiosarcoma Presenting as an Acute Intraabdominal Hemorrhage Treated with Transarterial Chemoembolization

Stambo, Glenn W.; Guiney, Michael

doi:10.1155/2007/90169

Cited by 16 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported a PHA patient who underwent right lobe transjugular liver biopsy (three separate biopsies) and only showed nonbridging portal fibrosis, extensive sinusoidal fibrosis, and panlobular in some areas, and at last the patient was diagnosed after liver transplant . Failure or mistake of diagnosis by CT or ultrasound‐guided fine‐needle aspiration biopsy has also been reported by different institutions . What is more, Egea et al .…”

Section: Imaging and Pathological Diagnosismentioning

confidence: 98%

“…31 Failure or mistake of diagnosis by CT or ultrasound-guided fine-needle aspiration biopsy has also been reported by different institutions. [32][33][34][35][36] What is more, Egea et al 35 reported a PHA patient who had peritoneal bleeding 48 h after fine-needle biopsy, and Rademaker et al 21 reported a patient who developed a huge subcapsular hematoma after biopsy. Therefore, nonsurgical biopsy is generally avoided, and open liver biopsies or laparoscopy will be more accurate and safe.…”

Section: Imaging and Pathological Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Primary hepatic angiosarcoma and potential treatment options

Zheng

Zhang

et al. 2014

J of Gastro and Hepatol

117

View full text Add to dashboard Cite

Angiosarcomas account for a mere 2-3% of adult soft tissue sarcomas, with an overall poor outcome. Depending on the primary site, angiosarcomas have distinct prognosis. Primary hepatic angiosarcomas (PHAs) are much rare tumors, with worse prognosis compared with other angiosarcomas. PHA is reported to be associated with vinyl chloride, but the majority of patients were still with unknown etiology. As PHA lacks specific symptoms, signs, or images, pathological diagnosis is necessary. The review summarizes 25 articles published from January 2000 to December 2012, including 64 cases of PHA with detailed information. Survival curves are estimated using the Kaplan-Meier method by SPSS 21.0. We find that the median survival time is 5 months; local excision alone or combination with adjuvant therapy is the optimal choice, with median survival time of 17 months. In addition, liver transplant is abandoned for high recurrence rate; emergent transcatheter arterial embolization is thought to be an efficient method for controlling intra-abdominal bleeding; and transcatheter arterial chemoembolization and chemotherapy may be helpful in improving survival.

show abstract

Section: Imaging and Pathological Diagnosismentioning

confidence: 98%

Section: Imaging and Pathological Diagnosismentioning

confidence: 99%

Primary hepatic angiosarcoma and potential treatment options

Zheng

Zhang

et al. 2014

J of Gastro and Hepatol

117

View full text Add to dashboard Cite

show abstract

“…There have also been reports of arterial chemoembolisation in localized osteosarcoma 14 and hepatic angiosarcoma. 15,16 Percutaneous ethanol injection involves introducing single or multiple fine needles into the metastatic lesion and injecting ethanol (90-100%), thus causing cell death mainly by M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 13 dehydration. 17 A randomized trial of 232 patients with small hepatocellular carcinomas demonstrated those treated with radiofrequency ablation to have significantly longer survival compared to those treated with percutaneous ethanol injection.…”

Section: Accepted Manuscript 12mentioning

confidence: 99%

Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma

Jones

McCall

Adam

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

The role of radiofrequency ablation (RFA) in metastatic sarcoma is not well defined. The aim of this study was to evaluate the efficacy and safety of RFA in a series of sarcoma patients. A retrospective search of a prospectively maintained database identified 13 gastrointestinal stromal tumour (GIST) patients and 12 with other histological subtypes treated with RFA. All the GIST patients received RFA for metastatic disease in the liver: 12 of these responded to the first RFA procedure and one achieved stable disease. Two GIST patients received RFA on two occasions to separate lesions within the liver and both responded to the second RFA procedure. Of the other subtypes: 7 underwent RFA to liver lesions, 5 of these responded to RFA, one progressed and 1 was not assessable for response at the time of analysis. All 5 patients with lung metastases achieved a response following their first RFA procedure. RFA was effective and well tolerated in this series of sarcoma patients. RFA may have a role in patients with GIST who have progression in a single metastasis but stable disease elsewhere. Further larger studies are required to better define the role of this technique in this patient population.

show abstract

“…[ [4][5][6][7][8] TACE has shown improved patient survival rates compared to conservative treatment for various types of malignant liver tumors.…”

Section: [1-3]mentioning

confidence: 99%

“…[5][6][7][8] This combination produces elevated local chemotherapeutic drug levels along with vascular occlusion of the feeding vessels killing the tumor resulting in reduced systemic toxicity without causing collateral damage to the surrounding liver parenchyma.…”

Section: [1-3]mentioning

confidence: 99%

Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy

Stambo¹,

Cragan²

2017

View full text Add to dashboard Cite

How to cite this article: Stambo GS, Cragan D. Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy. Hepatoma Res 2017;3:141-8. Aim:The purpose of this study was to evaluate and compare how hepatocellular carcinoma (HCC) and colorectal metastases respond to LC Bead chemoembolization using doxorubicin and irinotecan. Methods: The authors report their experience with doxorubicin and irinotecan eluting beads to treat 13 patients with primary HCC and 25 patients with colorectal metastases over a 1-year period at a single community based oncology practice. Within the colorectal cancer group they compared irinotecan eluting beads to doxorubicin eluting beads. Results: Nine of the 11 (81.8%) doxorubicin treated HCC patients had either complete response or partial response. All of the HCC lesions showed reduction in size and tumor enhancement and 10/11 (91%) HCC patients were alive at 24 months post treatment. Fisher's exact test revealed that among the 22 with colorectal metastases for whom follow-up data were available, those 11 who were treated with doxorubicin were significantly more likely to demonstrate complete or partial response compared to the 11 in the irinotecan treated group (P < 0.001). Conclusion: Overall, HCC and colon metastasis patients clearly demonstrated the effectiveness of drug eluting beads with 91% of the HCC patients alive 24 months after treatment. Key words:Angiography, transarterial chemoembolization, drug eluting beads, hepatocellular carcinoma, doxorubicin, irinotecan ABSTRACTArticle history:

show abstract

Hepatic Angiosarcoma Presenting as an Acute Intraabdominal Hemorrhage Treated with Transarterial Chemoembolization

Cited by 16 publications

References 12 publications

Primary hepatic angiosarcoma and potential treatment options

Primary hepatic angiosarcoma and potential treatment options

Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma

Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy

Contact Info

Product

Resources

About